Mesoblast Statistics

Total Valuation

Mesoblast has a market cap or net worth of AUD 3.82 billion. The enterprise value is 3.91 billion.

Market Cap	3.82B
Enterprise Value	3.91B

Important Dates

The next estimated earnings date is Monday, February 24, 2025.

Earnings Date	Feb 24, 2025
Ex-Dividend Date	n/a

Share Statistics

Mesoblast has 1.14 billion shares outstanding. The number of shares has increased by 26.87% in one year.

Current Share Class	n/a
Shares Outstanding	1.14B
Shares Change (YoY)	+26.87%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	42.95%
Owned by Institutions (%)	27.20%
Float	635.17M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
PB Ratio	5.31
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-29.64
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-53.50

Financial Position

The company has a current ratio of 1.18, with a Debt / Equity ratio of 0.25.

Current Ratio	1.18
Quick Ratio	1.14
Debt / Equity	0.25
Debt / EBITDA	n/a
Debt / FCF	-2.44
Interest Coverage	-2.81

Financial Efficiency

Return on equity (ROE) is -17.91% and return on invested capital (ROIC) is -5.95%.

Return on Equity (ROE)	-17.91%
Return on Assets (ROA)	-5.41%
Return on Capital (ROIC)	-5.95%
Revenue Per Employee	121,177
Profits Per Employee	-1.81M
Employee Count	73
Asset Turnover	0.01
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +974.19% in the last 52 weeks. The beta is 2.38, so Mesoblast's price volatility has been higher than the market average.

Beta (5Y)	2.38
52-Week Price Change	+974.19%
50-Day Moving Average	1.90
200-Day Moving Average	1.29
Relative Strength Index (RSI)	76.36
Average Volume (20 Days)	15,515,202

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Mesoblast had revenue of AUD 8.85 million and -131.83 million in losses. Loss per share was -0.13.

Revenue	8.85M
Gross Profit	-52.71M
Operating Income	-86.89M
Pretax Income	-132.11M
Net Income	-131.83M
EBITDA	-84.05M
EBIT	-86.89M
Loss Per Share	-0.13

Full Income Statement

Balance Sheet

The company has 94.36 million in cash and 178.24 million in debt, giving a net cash position of -83.88 million or -0.07 per share.

Cash & Cash Equivalents	94.36M
Total Debt	178.24M
Net Cash	-83.88M
Net Cash Per Share	-0.07
Equity (Book Value)	719.96M
Book Value Per Share	0.63
Working Capital	19.81M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -72.63 million and capital expenditures -406,175, giving a free cash flow of -73.04 million.

Operating Cash Flow	-72.63M
Capital Expenditures	-406,175
Free Cash Flow	-73.04M
FCF Per Share	-0.06

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	-982.24%
Pretax Margin	-1,493.51%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Mesoblast does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-26.87%
Shareholder Yield	-26.87%
Earnings Yield	n/a
FCF Yield	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Mesoblast has an Altman Z-Score of -0.92. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-0.92
Piotroski F-Score	n/a